Caller further described it as contact dermatitis but without contact; She says the rash is not vesicle rash, it is plaque like and very itchy; she started having hypersensitivity reactions; rash last week; This is a spontaneous report received from contactable reporter(s) (Nurse) from medical information team. The reporter is the patient.  A 65-year-old female patient received BNT162b2 (COMIRNATY), on 29Oct2021 as dose 3 (booster), single (Lot number: FG3527) at the age of 64 years for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (first dose was 28Mar2021 of Pfizer LOT: EP6955), administration date: 28Mar2021, when the patient was 64-year-old, for Covid-19 immunization; BNT162b2 (second dose was 18Apr2021 of LOT: EW0161), administration date: 18Apr2021, when the patient was 64-year-old, for Covid-19 immunization.  The following information was reported: RASH (non-serious) with onset Apr2022, outcome "unknown", described as "rash last week"; HYPERSENSITIVITY (non-serious) with onset Apr2022, outcome "unknown", described as "she started having hypersensitivity reactions"; DERMATITIS (non-serious), outcome "unknown", described as "Caller further described it as contact dermatitis but without contact"; RASH PRURITIC (non-serious), outcome "unknown", described as "She says the rash is not vesicle rash, it is plaque like and very itchy". The events "she started having hypersensitivity reactions", "rash last week", "caller further described it as contact dermatitis but without contact" and "she says the rash is not vesicle rash, it is plaque like and very itchy" required physician office visit. Therapeutic measures were taken as a result of hypersensitivity, rash, dermatitis.  Additional information: calling as patient about Comirnaty or the Pfizer BioNTech COVID-19 vaccine. She says whoever named Comirnaty, the name doesn't roll off the tongue. She says she is a nurse who works ironically. Caller does not clarify this statement. Caller says she developed a rash, and the last time she had a dose of the drug was 29Oct, which was her booster dose. She says she had two previous doses, and has not been dosed since then. She says the rash that developed she believes is a hypersensitivity reaction to something, this rash that she has never had before and is not like poison ivy. She says she went to see a physician who gave her a cream. She says she is wondering if they have seen this type of skin rash develop this far off from dosing or if it could be considered a hypersensitivity reaction. Reporter says the rash started or she became aware of it last Tuesday, so it maybe started on Monday. She says the rash started on her right calf then moved up the inside of her right knee, then went to right thigh, and now she has it on left calf. She says the rash has a plaque like quality to it in areas, and is almost like contact dermatitis, but there is nothing here. She says the rash is not vesicle rash, it is plaque like and very itchy. She says her theory is whatever the mRNA vaccine is doing to her immune system, it has revved up after contact with something when alerted. She says her theory could be wrong. She says she also has a little around her right hip and a little under her left arm this morning. She says she would say where the original rash was to her left calf is improving over time.  She says he had the ointment, and her provider gave her Triamcinolone cream, which she prefers the ointment because she feels like the ointment works better. No follow-up attempts are possible. No further information is expected.